ArticleProstate international2024

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.

Alicia López-Abad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.